SCHEDULE 13D: Elray Resources and Anthony Goodman Disclose Majority Stake in 180 Life Sciences Following Blockchain Casino Asset Sale

Sentiment:

Beneficial Ownership Disclosure


Anthony Brian Goodman and Elray Resources, Inc. have disclosed a 57.6% beneficial ownership stake in 180 Life Sciences Corp. following the sale of blockchain casino intellectual property in exchange for convertible preferred stock and warrants.

Summary

  • Reporting Persons Anthony Brian Goodman and Elray Resources, Inc. now beneficially own 4,318,000 shares of 180 Life Sciences Corp. common stock, representing 57.6% of the outstanding class.
  • This ownership stems from an Asset Purchase Agreement dated September 29, 2024, where Elray sold source code and intellectual property for an online blockchain casino to 180 Life Sciences Corp.
  • In consideration, Elray received 1,000,000 shares of newly designated Series B Convertible Preferred Stock and warrants to purchase 3,000,000 shares of common stock.
  • The Series B Preferred Stock is convertible into 1,318,000 shares of common stock at a 1.318-for-1 ratio.
  • The warrants are exercisable for 3,000,000 shares of common stock at an exercise price of $1.68 per share, with a seven-year term expiring on September 30, 2031.
  • Shareholder approval for the issuance of these shares was received on December 27, 2024, making the preferred stock convertible and warrants exercisable.
  • Elray will provide six months of post-closing assistance at no cost to 180 Life Sciences Corp. for building and launching the casino operation, including help with payment gateways and licensing.

Sentiment

Score: 6

Explanation: The document details a significant strategic transaction and a substantial change in beneficial ownership. While it introduces a new business line for 180 Life Sciences, the immediate financial implications and the long-term success of the new venture are not detailed. The large equity stake by the seller could be seen positively for alignment but also raises questions about control and potential dilution. The 'expected' nature of the outcome (shareholder approval) prevents a higher score, as there are no new, unexpected positive developments.

Positives

  • 180 Life Sciences Corp. acquired source code and intellectual property for an online blockchain casino, potentially diversifying its business into a new growth area.
  • Elray Resources, Inc. will provide six months of post-closing assistance at no additional cost to 180 Life Sciences Corp. for launching the casino operation, which includes support for payment gateways and licensing.
  • The transaction structure, involving equity and warrants as consideration, aligns the interests of the seller (Elray) with the long-term success of 180 Life Sciences Corp. by making them a significant shareholder.

Negatives

  • The acquisition significantly dilutes existing common shareholders, as the reporting persons now hold 57.6% of the company's common stock on a fully diluted basis.
  • 180 Life Sciences Corp. will need to negotiate and potentially incur additional costs for 'Front-End Development' of the casino, which was not included in the initial asset purchase.
  • Elray retains the right to use the purchased assets for its own SAAS solutions and hosted casino solutions to third parties, which could imply potential competition or less exclusivity for 180 Life Sciences Corp.

Risks

  • The success of the new online blockchain casino operation is dependent on Elray's post-closing assistance and 180 Life Sciences Corp.'s ability to secure necessary front-end development, payment gateways, and licensing.
  • The significant beneficial ownership by the Reporting Persons (57.6%) could give them substantial control over company decisions, potentially impacting the interests of minority shareholders.
  • The company's ability to successfully integrate and monetize the acquired blockchain casino assets in a competitive and evolving market is uncertain.

Future Outlook

The Reporting Persons acquired the securities for investment purposes and may purchase additional securities of the Issuer or dispose of some or all of the securities they currently own from time to time, depending on general market and economic conditions. They currently have no plans or proposals for extraordinary corporate transactions, changes in the board or management, or material changes to the Issuer's capitalization or dividend policy, but they retain the right to change their investment intent.

Industry Context

This filing indicates 180 Life Sciences Corp.'s strategic move into the online blockchain casino sector, a rapidly evolving segment within the broader gaming and technology industries. The acquisition of intellectual property and the subsequent significant equity stake by Elray Resources, Inc., a developer of online gaming platforms, suggests a pivot or diversification strategy for 180 Life Sciences Corp. This aligns with a trend of companies exploring new revenue streams in digital and blockchain-based entertainment, though the specific competitive landscape and market positioning for 180 Life Sciences Corp. in this new venture are not detailed.

Corporate Governance

Change TypeDescriptionEffective DateImpact Assessment
Preferred Stock DesignationThe Company's Board of Directors approved the adoption and filing of a Certificate of Designations for Series B Convertible Preferred Stock, establishing its designations, preferences, limitations, and relative rights.2024-09-30This created a new class of preferred stock with specific voting, dividend, and liquidation rights, impacting the company's capital structure and governance, particularly regarding protective provisions requiring Series B holder consent for certain actions.

Related Party Transactions

  • The Asset Purchase Agreement between 180 Life Sciences Corp. and Elray Resources, Inc. is a related party transaction, as Anthony Brian Goodman, a Reporting Person, is the Chief Executive Officer of Elray and now a significant beneficial owner of 180 Life Sciences Corp.

Stakeholder Impact

  • **Shareholders**: Existing common shareholders face significant dilution due to the issuance of convertible preferred stock and warrants, which, upon conversion/exercise, represent 57.6% of the company's common stock. The transaction also introduces a new business line (online blockchain casino) which could impact future revenue and risk profile.
  • **Management/Board**: The significant beneficial ownership by the Reporting Persons could influence future strategic decisions and potentially board composition, although no immediate changes are stated.
  • **Customers/Suppliers**: The acquisition of blockchain casino assets suggests a new product offering, potentially impacting future customers in the online gaming space. New suppliers for front-end development and payment gateways will be sought.

Next Steps

  • Elray Resources, Inc. will provide post-closing assistance to 180 Life Sciences Corp. for six months to build and launch the online casino operation.
  • 180 Life Sciences Corp. and Elray Resources, Inc. will negotiate in good faith for Elray to assist with Front-End Development for an additional cost, or Elray will introduce a vendor for this purpose.
  • The Reporting Persons may purchase additional securities or dispose of existing holdings in the future, depending on market conditions.

Key Dates

DateDescription
2024-09-29Asset Purchase Agreement entered into between 180 Life Sciences Corp. and Elray Resources, Inc.
2024-09-29Verbal fairness opinion received from Hempstead & Co., LLC regarding the purchase price.
2024-09-30Closing of the Asset Purchase Agreement transactions.
2024-09-30Certificate of Designations for Series B Convertible Preferred Stock filed and became effective.
2024-09-30Common Stock Purchase Warrants granted to Elray Resources, Inc.
2024-12-27180 Life Sciences Corp. held its 2024 Annual Meeting of Stockholders, where Stockholder Approval was received for the issuance of Conversion Shares and Warrant Shares.
2024-12-27Effective date for Series B Preferred Stock to become convertible and Warrants to become exercisable.
2025-01-08Date as of which 3,176,999 shares of Common Stock were outstanding, as confirmed by the Transfer Agent.
2025-01-10Date of filing of this Schedule 13D.
2031-09-30Expiration date of the Warrants (seven-year term from September 30, 2024).

Keywords

180 Life Sciences Corp., Elray Resources Inc., Anthony Brian Goodman, Schedule 13D, beneficial ownership, asset purchase agreement, blockchain casino, convertible preferred stock, warrants, shareholder approval, corporate governance, SEC filing, equity stake, online gaming

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.